Brief: Summit Therapeutics Q4 Net Income USD -219.2 Million
23/02/2026 21:05
Feb 23 (Reuters) - Summit Therapeutics Q4 operating expenses USD 225 million. Q4 EPS USD -0.29
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering